Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tempest Therapeutics, Inc.MLND · Entity 7734 | Chief Development Officer | May 25, 2020 | May 28, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tempest Therapeutics, Inc.
Report date May 25, 2020 · Filed May 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2030-05-24 | Direct | 80,000 |
Reported balance
After 2020-05-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-25 · Grant · Acquired 80,000 · Balance 80,000 F1: Fifty percent (50%) of the shares subject to this option shall vest on the earlier of: (i) December 31, 2020 or (ii) the Board's approval of the achievement of certain performance criteria, and one twelfth (1/12th) of the remaining shares subject to this option shall vest in equal monthly installments thereafter, subject to the Reporting Person continuing to provide service to the Issuer through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Fifty percent (50%) of the shares subject to this option shall vest on the earlier of: (i) December 31, 2020 or (ii) the Board's approval of the achievement of certain performance criteria, and one twelfth (1/12th) of the remaining shares subject to this option shall vest in equal monthly installments thereafter, subject to the Reporting Person continuing to provide service to the Issuer through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2020 Filed May 28, 2020 01:40 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032488 · doc4.xml · derivative · entry 1 Zeidan Ryan · CIK 0001785724 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-05-24 F1 · derivative.exercise_date: Fifty percent (50%) of the shares subject to this option shall vest on the earlier of: (i) December 31, 2020 or (ii) the Board's approval of the achievement of certain performance criteria, and one twelfth (1/12th) of the remaining shares subject to this option shall vest in equal monthly installments thereafter, subject to the Reporting Person continuing to provide service to the Issuer through each such date. Read SEC document |
| March 28, 2020 Filed Mar 31, 2020 21:03 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001209191-20-021851 · doc4.xml · derivative · entry 1 Zeidan Ryan · CIK 0001785724 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-03-27 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option shall vest on March 28, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:30 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 41,250 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001209191-20-006355 · doc4.xml · derivative · entry 1 Zeidan Ryan · CIK 0001785724 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,250 Underlying: Common Stock · 41,250 shares Expires 2030-01-30 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option shall vest on January 7, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 00:38 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001209191-19-046917 · doc4.xml · derivative · entry 1 Zeidan Ryan · CIK 0001785724 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-08-18 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option shall vest on August 19, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.